Dr. Ljubenkov is a behavioral neurologist with 7 years of experience as an investigator in numerous clinical trials enrolling patients with neurodegenerative disease. Most notably, he is a primary investigator for Veri-T: A Trial of Verdiperstat in Patients With svPPA (semantic variant primary progressive aphasia) Due to TDP-43 Pathology. Veri-T is the first clinical trial in patients with svPPA and the first NIH-funded multi-site trial serving patients with frontotemporal dementia. Additionally he is currently the designated primary investigator (PI) for INFRONT-3, an international multi-center study which is the first phase 3 clinical therapeutic trial in patients with frontotemporal dementia due to progranulin deficiency. He has also served as UCSF’s site PI for multiple clinical trials enrolling participants with Alzheimer’s and FTLD spectrum disease and served as medical monitor for multiple clinical studies, including the first phase 1 parallel cohort “basket design” clinical trial in patients with primary tauopathies.